Where does Celgene International II Sàrl rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celgene International II Sàrl ranks #15,175 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celgene International II Sàrl hold?

Celgene International II Sàrl holds 19 US utility patents granted between 2016 and 2024, spanning 14 technology areas.

What is Celgene International II Sàrl's Innovation Score?

Celgene International II Sàrl has an Innovation Score of 37.8 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Celgene International II Sàrl focus on?

Celgene International II Sàrl's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 14 CPC subclasses total.

Is Celgene International II Sàrl's patent grant rate increasing or decreasing?

Celgene International II Sàrl's recent grant velocity is -42% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Celgene International II Sàrl's patents?

Celgene International II Sàrl's patents average 22.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celgene International II Sàrl patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Celgene International II Sàrl

USPTO PatentsView assignee record - 19 granted patents across 14 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Celgene ranks #15,175 of 49,997 tracked US assignees by granted-patent volume, with 19 patents across 14 technology areas.

#15,175
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.8/100): 22.3
avg claims per patent: -42%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15175 · Foreign Corporation #15,175 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 19 grants
MID-PACK #15,175/49,997
PHOTO-FINISH Calyan
CPC-FOCUS A61P · 14 areas
INNOV-THIN 37.8/100
CLAIMS-DENSE 22.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -42% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Calyan Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Celgene’s 37.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.3 pts (27%) Velocity 0.8 pts (2%) Breadth 13.2 pts (35%) Claim depth 13.4 pts (36%)

Qualcomm Incorporated · highest

85
Celgene Internationa… · this assignee

38
3D Lighting… · lowest

7

What this shows Celgene's Innovation Score is 37.8/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Celgene?

Each dot is one of Celgene’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Celgene’s own 22.3 claims/patent is ABOVE the 11.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Celgene vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Celgene's grants concentrate

Celgene International II Sàrl is a focused PatentsView assignee: 14 CPC subclasses with 73.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2024. By volume, Celgene sits between Calyan Technologies, Inc. and Chengdu Tianma Micro-Electronics Co., Ltd..

Celgene's three-year grant acceleration

Celgene International II Sàrl shows 1 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Calyan

19
Cardiofocus

19
Carol Cole

19
Catabasis Pharmac…

19
Celularity

19
Champion Engine T…

19
Cheng Shin Rubber…

19
Chengdu Tianma Mi…

19
Celgene Internati… ◀

19

What this shows Celgene holds 19 patents at rank #15,198, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celgene

By rank, the assignees closest to #15,198 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Celgene's primary technology class.

Celgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Celgene International II Sàrl patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	3	15.8%
2017	4	21.1%
2018	3	15.8%
2019	2	10.5%
2020	4	21.1%
2021	2	10.5%
2024	1	5.3%

Which technologies does Celgene International II Sàrl patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

C07D - Heterocyclic Compounds 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C07K - Peptides 3

C07C - Acyclic OR Carbocyclic Compounds 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C08B - POLYSACCHARIDES; Derivatives Thereof 1

C08L - Compositions OF Macromolecular Compounds 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

Top 14 of 14 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Celgene International II Sàrl's patent record in context - here's where to go next.

Celgene International II Sàrl's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 73.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #15,175 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Celgene International II Sàrl against Calyan Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.